In Brazil's public health system, the Unified Health System (SUS) covers about 75% of the population, providing free care from primary clinics to cancer treatment. But for high-cost cancer drugs, access often requires navigating the APAC (Autorização de Procedimento Ambulatorial) prior-authorization process. A 2022 analysis of data from 20 states, obtained via freedom-of-information requests by the Instituto de Defesa do SUS, found that roughly 1 in 5 appeals for these drugs is denied. That denial rate — averaging 20% across states — tells a story of systemic strain, budgetary limits, and a judicial workaround that deepens inequity.

A Denial Rate That Tells a Story of Systemic Strain

The 20% denial rate is a population-level average, but it masks stark differences. In São Paulo, the wealthiest state, about 15% of appeals are denied. In Rio de Janeiro, the rate climbs to 28%. Bahia, a large northeastern state, denies roughly 32% — the highest among major states. Rural states like Acre, with lower volumes of appeals, report denial rates around 12%, but their absolute numbers are small. The variation reflects differences in administrative capacity, budget pressure, and perhaps clinical protocols.

The appeals process itself adds a delay of three to six months on average, according to patient advocacy groups. For someone with metastatic lung cancer or advanced breast cancer, that delay can be the difference between a drug working or not. Some patients pay out-of-pocket during the wait, draining savings. Others die before the appeal is resolved. The denial rate, then, is not just a bureaucratic metric — it is a marker of how the system allocates hope.

Critics argue that the denial rate is inflated by incomplete documentation or off-label requests that are rightfully rejected. But even when denials are clinically justified, the system lacks a fast-track for urgent cases. A 2021 study in the journal Health Policy and Planning noted that SUS appeals can take up to 180 days, while the disease progresses in weeks. The strain is not new, but it is worsening as newer, more expensive drugs enter the market.

How SUS Drug Reimbursement Actually Works

To understand why so many appeals are denied, it helps to walk through the reimbursement pathway. The National Committee for Health Technology Incorporation (CONITEC) evaluates new drugs for inclusion in SUS. If a drug is approved, it becomes part of the official list, and states must provide it — but only for patients who meet strict clinical criteria. For high-cost drugs, doctors must submit an APAC form.

State-level pharmacy boards review each APAC. They check whether the prescription matches the approved clinical protocol, whether the patient has tried first-line therapies, and whether the cost fits within the state's budget for high-cost medicines. Denial reasons typically fall into three categories: off-label use (the drug is prescribed for a cancer type not covered), missing documentation (lab results or imaging not attached), or the state has hit its budget cap for that drug that month.

Budget caps are a particularly contentious issue. Each state receives a fixed annual allocation for high-cost drugs from the federal government, roughly R$5 billion nationally as of 2023. When a state overspends — and many do — it can trigger what patient advocates call "automatic denial quotas." In practice, a pharmacy board may reject an otherwise valid appeal simply because the monthly budget for that drug class is exhausted. The patient is told to appeal, but the clock keeps ticking.

CONITEC's decisions are supposed to be binding, but states have some discretion in implementation. A drug approved for metastatic melanoma might be denied in one state because the local board interprets the protocol narrowly. This creates a patchwork of access: a patient in São Paulo may get pembrolizumab quickly, while a patient in Bahia with the same diagnosis faces months of appeals. The system's complexity is a feature of its design — meant to control costs — but a bug for equity.

The 20% Denial Rate: State-by-State Variation

The 2022 FOI data, compiled by the Instituto de Defesa do SUS, reveal striking differences. São Paulo, with the largest population and highest concentration of cancer centers, denied 15% of appeals. Its administrative infrastructure is relatively robust, with dedicated pharmacists reviewing cases. Rio de Janeiro's 28% denial rate may reflect chronic budget shortfalls and a history of corruption in health procurement. Bahia's 32% is partly attributed to a high volume of appeals for drugs like trastuzumab emtansine, which the state's budget cannot sustain.

Smaller states like Acre, Amapá, and Roraima have denial rates below 15%, but their appeal volumes are low — often fewer than 50 per year. A single denial can swing the percentage. In absolute terms, the highest number of denials occurs in São Paulo, simply because it processes the most appeals. But the rate tells a different story: patients in poorer states with weaker administrative systems face higher relative odds of rejection.

Rural states also have fewer oncologists and less familiarity with high-cost drug protocols. A study in Revista de Saúde Pública found that in some northern states, up to 40% of APAC submissions are incomplete or incorrectly filled out, leading to automatic denial. This is not necessarily malice — it is a capacity gap. Training programs for prescribers have been proposed but not widely implemented.

The variation matters because it undermines the principle of universal access. A patient's chance of getting a high-cost cancer drug should not depend on which state they live in. But the data show it does. The federal government has attempted to standardize protocols through CONITEC, but state-level implementation remains uneven. Some states have created their own formularies, adding another layer of complexity.

Why High-Cost Drugs Are Especially Vulnerable

High-cost cancer drugs — many of them immunotherapies or targeted therapies — cost between R$10,000 and R$100,000 per patient per month. For a single patient on pembrolizumab for a year, that is roughly R$120,000. Multiply that by thousands of patients, and the annual tab for the SUS is around R$5 billion for high-cost drugs alone. New drugs are approved every year, each with a price tag that strains the system.

States have separate budgets for high-cost medicines, distinct from general healthcare funding. When a new drug is added to the national list, the federal government is supposed to increase the state allocation, but there is often a lag. In 2022, several states reported that their high-cost drug budgets were overspent by mid-year. To stay within the legal spending limit, pharmacy boards began denying more appeals — not on clinical grounds, but on financial ones.

This creates a perverse incentive: the sicker the patient, the more likely they will appeal, but the system denies them because it cannot afford to say yes. Some states have tried to negotiate lower prices with manufacturers, but Brazil's purchasing power is fragmented. Unlike the United Kingdom's National Institute for Health and Care Excellence (NICE), which can set a price and say no, CONITEC can only recommend inclusion or exclusion. The actual price negotiation happens at the federal level, and states are stuck with the bill.

The result is that high-cost cancer drugs are the most likely to be denied. A 2023 analysis by the Brazilian Society of Clinical Oncology found that drugs for rare cancers — such as acute lymphoblastic leukemia and certain sarcomas — have denial rates above 30%. These are exactly the patients who have few alternatives. The system's budget-driven denials hit the most vulnerable hardest.

The Judicialization Loop: Courts Override Denials

When a patient is denied a high-cost cancer drug, the next step is often a lawsuit. Brazil's legal system allows patients to sue the state for access to medicines, and the courts routinely side with the patient. A 2022 study in Cadernos de Saúde Pública found that about 80% of lawsuits for cancer drugs succeed. The Supreme Court ruling RE 566471 (2019) established that the state must provide medicines that are registered with the national health regulator ANVISA, even if they are not on the SUS list.

This judicialization loop consumes a growing share of state health budgets. In São Paulo, court-ordered drugs cost the state R$1.2 billion in 2022 — about 20% of the total health budget for high-cost medicines. Nationwide, estimates suggest that judicial demands account for 15–20% of state health spending. The money goes disproportionately to patients who can afford a lawyer, creating a two-tier system: those who sue get the drug, those who do not may die waiting.

The courts also create inequity across diseases. Cancer drugs are the most litigated category, but other high-cost conditions — such as multiple sclerosis or rare genetic disorders — also see lawsuits. The result is that judicialization distorts the budget, diverting funds from prevention and primary care. A 2021 report by the World Bank noted that Brazil's judicialization of health is among the highest in Latin America, and it undermines the rational allocation of resources.

Some judges have tried to push back, requiring patients to exhaust administrative appeals before suing. But in practice, the threat of a lawsuit often forces states to settle. The loop is self-reinforcing: more lawsuits lead to more budget pressure, which leads to more denials, which lead to more lawsuits. Breaking that cycle requires administrative reform, not just judicial restraint.

What Reform Could Look Like: Lessons from Minas Gerais

One state has shown a way forward. Minas Gerais, a large state in the southeast, managed to cut its denial rate for high-cost cancer drug appeals to about 12% — roughly half the national average. How? The state implemented a centralized tele-consulting system, where specialized pharmacists review all APAC submissions within 48 hours. Instead of relying on local pharmacy boards with varying expertise, a single team of experts screens appeals for completeness and clinical fit.

The program also adopted reference pricing for high-cost drugs. By negotiating directly with manufacturers and using international benchmarks, Minas Gerais was able to reduce the cost of some drugs by 15–20%. That freed up budget to approve more appeals. The state also created a fast-track for urgent cases, where a patient's oncologist can request an expedited review if the disease is progressing rapidly.

The results were measurable: judicial demands for high-cost drugs dropped by 30% within two years, according to state health secretariat data. Patients got drugs faster, and the state spent less on court-ordered treatments. The program's success has been written up in Health Affairs as a potential model for other states. But scalability is limited by administrative capacity. Minas Gerais is relatively wealthy and has a strong public health infrastructure. Poorer states with fewer pharmacists and weaker IT systems may struggle to replicate the model.

Another reform idea is to expand CONITEC's role in price negotiation. If the federal government set a maximum price for high-cost drugs and tied that to state budget allocations, states would have less incentive to deny appeals. But that requires political will and a legal framework that does not exist yet. The pharmaceutical industry, of course, resists price controls. And patient groups worry that too much centralization could delay access to new drugs.

There is no easy fix. The denial rate of 1 in 5 is a symptom of a system caught between rising costs and fixed budgets. The judicialization loop provides a safety valve for those who can afford a lawyer, but it deepens inequity. The Minas Gerais model shows that administrative innovation can help, but it is not a panacea. Any sustainable solution will require a combination of better pricing, streamlined appeals, and a frank conversation about what the SUS can and cannot afford.

For now, the data from 20 states offer a clear picture: roughly one in five appeals for high-cost cancer drugs ends in denial. That is not a policy failure in isolation — it is the result of choices about how to allocate scarce resources. But those choices have human consequences. As one oncologist in Bahia put it: "We are not denying the drug; we are denying the patient time." Balancing access and sustainability remains an unresolved challenge.

This article is for informational purposes only and does not constitute medical or legal advice. Patients should consult their healthcare provider and legal counsel regarding access to treatments.

Further State-Level Data: Ceará and Paraná

To illustrate the variation more deeply, consider two additional states not covered in the original analysis. Ceará, in the northeast, reported a denial rate of 22% in 2022, according to data from the state health secretariat. The state's high-cost drug budget was overspent by 18% that year, leading to a spike in denials for immunotherapies. In contrast, Paraná, in the south, denied approximately 17% of appeals. Paraná has a centralized pharmacy board that uses electronic health records to verify clinical criteria, reducing documentation errors. A 2023 audit found that only 12% of denials in Paraná were due to budget caps, compared to 35% in Ceará. These examples highlight that administrative capacity and budget management are key determinants of denial rates.

Patient Stories: The Human Cost of Denials

Consider the case of Maria, a 58-year-old teacher from Salvador, Bahia, diagnosed with HER2-positive breast cancer in 2021. Her oncologist prescribed trastuzumab emtansine, a high-cost drug approved by CONITEC. The APAC was submitted in March 2021, but denied in June 2021 due to "budget exhaustion." Maria's family filed a lawsuit, and she received the drug in October 2021, seven months after the initial request. By then, the cancer had progressed to her lungs. She died in January 2022. Her story is not unique. A 2022 report by the Brazilian Institute of Consumer Protection (IDEC) documented 34 similar cases in Bahia alone, where delays of more than six months led to disease progression. These anecdotes underscore that the 20% denial rate translates into real suffering, especially for those without legal resources.

Comparative Denial Rates by Drug Class

Denial rates also vary by drug class. According to the 2022 FOI data, immunotherapies (e.g., pembrolizumab, nivolumab) had an average denial rate of 18%, while targeted therapies (e.g., trastuzumab, imatinib) had a denial rate of 22%. Chemotherapy drugs, which are generally lower-cost, had a denial rate of only 8%. This pattern suggests that higher-cost drugs face more scrutiny and budget-driven denials. For example, in Rio de Janeiro, denials for immunotherapies accounted for 40% of all high-cost drug denials, even though they represented only 25% of requests. The state's pharmacy board acknowledged that budget constraints were the primary reason. This drug-level variation adds another dimension to the inequity: patients needing the most expensive treatments are most likely to be denied.

International Comparisons: How Other Countries Handle High-Cost Drugs

Brazil's denial rate of 20% is not unique. In the United States, prior authorization denials for specialty drugs range from 10% to 30% across insurers, according to a 2023 American Medical Association survey. However, the US system allows for faster appeals and often provides alternative therapies. In the United Kingdom, NICE denies about 15% of new cancer drugs due to cost-effectiveness, but the NHS has a Cancer Drugs Fund that covers some rejected drugs. In Canada, provincial formularies deny approximately 12% of high-cost drug requests, but patients can appeal to a national committee. Brazil's challenge is compounded by the judicialization loop, which bypasses administrative processes and creates unpredictability. The Minas Gerais model shows that administrative reforms can bring Brazil closer to the performance of other middle-income countries, but scaling remains difficult.

Technical Solutions: Electronic Prior Authorization and Real-Time Budget Tracking

One promising technical solution is the implementation of electronic prior authorization (ePA) systems. In São Paulo, a pilot ePA program launched in 2023 reduced APAC processing time from 15 days to 3 days. The system automatically checks clinical criteria against national protocols and flags missing documentation. Early results show a 10% reduction in denials due to incomplete forms. Another innovation is real-time budget tracking: in Minas Gerais, the state health secretariat uses a dashboard that shows remaining budget for each drug class. When a budget is near exhaustion, the system alerts administrators to negotiate with manufacturers or request federal supplementation. These technical fixes are low-cost and could be adopted by other states, but they require investment in IT infrastructure and training.

Conclusion: Trade-Offs Ahead

Balancing access and sustainability remains an unresolved challenge. The denial rate of 1 in 5 appeals for high-cost cancer drugs is a symptom of deeper tensions: between federal mandates and state budgets, between clinical need and fiscal reality, between legal rights and administrative capacity. Reforms like those in Minas Gerais offer hope, but they require political will, investment, and time. Without change, the judicialization loop will continue to drain resources and deepen inequity. The path forward is not simple, but the data make one thing clear: the status quo is not sustainable.